Phase 3 Trial of Ibrutinib plus Rituximab in WM (iNNOVATE)

Key Findings

• ●Ibrutinib-rituximab: 82% 30-month PFS vs 28% for placebo-rituximab (HR 0.20, P<0.001)
• ●Benefits seen regardless of prior treatment status
• ●Established ibrutinib-rituximab as standard of care

Referenced in (1 disease)